单药贝兰他单抗莫福汀对比泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤的疗效与安全性(DREAMM-3):一项3期、开放标签、随机研究
DREAMM-3研究在18个国家108个中心纳入325例既往≥2线治疗(含来那度胺和蛋白酶体抑制剂)后进展的复发或难治性多发性骨髓瘤患者,2:1随机分配至贝兰他单抗莫福汀组(218例)或泊马度胺联合低剂量地塞米松组(107例)。中位无进展生存期贝兰他单抗莫福汀组为11.2个月(95%CI 6.4-14.5),泊马度胺联合低剂量地塞米松组为7.0个月(95%CI 4.6-10.6),风险比1.03(95%CI 0.72-1.47;P=0.56),差异无统计学意义。贝兰他单抗莫福汀未显示新的安全性信号。
要点
- 贝兰他单抗莫福汀组中位无进展生存期11.2个月,泊马度胺联合低剂量地塞米松组7.0个月,风险比1.03(95%CI 0.72-1.47;P=0.56)。
- 贝兰他单抗莫福汀组最常见3-4级不良事件为血小板减少(23%)和贫血(16%)。
- 贝兰他单抗莫福汀组严重不良事件发生率为43%,泊马度胺联合低剂量地塞米松组为39%。
核心结论
- 贝兰他单抗莫福汀相比标准治疗未能统计学显著改善无进展生存期,但未观察到新的安全性信号。
- 贝兰他单抗莫福汀正在联合方案中用于复发或难治性多发性骨髓瘤的测试。
研究设计与样本
- DREAMM-3为开放标签3期随机研究,在18个国家108个中心开展。
- 纳入325例复发或难治性多发性骨髓瘤成人患者,按2:1随机分配至贝兰他单抗莫福汀组(218例)或泊马度胺联合低剂量地塞米松组(107例)。
- 贝兰他单抗莫福汀组给药方案为2.5 mg/kg静脉注射每21天一次;泊马度胺联合低剂量地塞米松组为泊马度胺4.0 mg口服每日(第1-21天)联合地塞米松40.0 mg(>75岁者20.0 mg)每周一次,28天为一周期。
- 主要终点为全部随机分配患者的无进展生存期;安全性人群为接受至少一剂研究治疗的全部随机分配患者。
- 数据截止日期为2022年9月12日,中位随访时间贝兰他单抗莫福汀组为11.5个月(5.5-17.6),泊马度胺联合低剂量地塞米松组为10.8个月(5.6-17.1)。
主要发现
- 中位无进展生存期贝兰他单抗莫福汀组为11.2个月(95%CI 6.4-14.5),泊马度胺联合低剂量地塞米松组为7.0个月(95%CI 4.6-10.6),风险比1.03(95%CI 0.72-1.47;P=0.56)。
- 贝兰他单抗莫福汀组最常见3-4级不良事件为血小板减少(49/217,23%)和贫血(35/217,16%)。
- 泊马度胺联合低剂量地塞米松组最常见3-4级不良事件为中性粒细胞减少(34/102,33%)和贫血(18/102,18%)。
- 严重不良事件贝兰他单抗莫福汀组发生94/217例(43%),泊马度胺联合低剂量地塞米松组发生40/102例(39%)。
- 贝兰他单抗莫福汀组无治疗相关死亡,泊马度胺联合低剂量地塞米松组有1例(1%)因脓毒症死亡。
关键数值与推荐
- 中位无进展生存期贝兰他单抗莫福汀组11.2个月(95%CI 6.4-14.5)对比泊马度胺联合低剂量地塞米松组7.0个月(95%CI 4.6-10.6),风险比1.03(95%CI 0.72-1.47;P=0.56)。
- 3-4级血小板减少贝兰他单抗莫福汀组49/217例(23%),泊马度胺联合低剂量地塞米松组未报告。
- 3-4级贫血贝兰他单抗莫福汀组35/217例(16%),泊马度胺联合低剂量地塞米松组18/102例(18%)。
- 3-4级中性粒细胞减少泊马度胺联合低剂量地塞米松组34/102例(33%),贝兰他单抗莫福汀组未报告。
- 严重不良事件贝兰他单抗莫福汀组94/217例(43%),泊马度胺联合低剂量地塞米松组40/102例(39%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple myeloma remains incurable, and heavily pretreated patients with relapsed or refractory disease have few good treatment options. Belantamab mafodotin showed promising results in a phase 2 study of patients with relapsed or refractory multiple myeloma at second or later relapse and a manageable adverse event profile. We aimed to assess the safety and efficacy of belantamab mafodotin in a phase 3 setting. METHODS: In the DREAMM-3 open-label phase 3 study, conducted at 108 sites across 18 countries, adult patients were enrolled who had confirmed multiple myeloma (International Myeloma Working Group criteria), ECOG performance status of 0-2, had received two or more previous lines of therapy, including two or more consecutive cycles of both lenalidomide and a proteasome inhibitor, and progressed on, or within, 60 days of completion of the previous treatment. Participants were randomly allocated using a central interactive response technology system (2:1) to receive belantamab mafodotin 2·5 mg/kg intravenously every 21 days, or oral pomalidomide 4·0 mg daily (days 1-21) and dexamethasone 40·0 mg (20·0 mg if >75 years) weekly in a 28-day cycle. Randomisation was stratified by previous anti-CD38 therapy, International Staging System stage, and number of previous therapies. The primary endpoint was progression-free survival in all patients who were randomly allocated. The safety population included all randomly allocated patients who received one or more doses of study treatment. This trial is registered with ClinicalTrials.gov, NCT04162210, and is ongoing. Data cutoff for this analysis was Sept 12, 2022. FINDINGS: Patients were recruited between April 2, 2020, and April 18, 2022. As of September, 2022, 325 patients were randomly allocated (218 to the belantamab mafodotin group and 107 to the pomalidomide-dexamethasone group); 184 (57%) of 325 were male and 141 (43%) of 325 were female, 246 (78%) of 316 were White. Median age was 68 years (IQR 60-74). Median follow-up was 11·5 months (5·5-17·6) for belantamab mafodotin and 10·8 months (5·6-17·1) for pomalidomide-dexamethasone. Median progression-free survival was 11·2 months (95% CI 6·4-14·5) for belantamab mafodotin and 7·0 months (4·6-10·6) for pomalidomide-dexamethasone (hazard ratio 1·03 [0·72-1·47]; p=0·56). Most common grade 3-4 adverse events were thrombocytopenia (49 [23%] of 217) and anaemia (35 [16%]) for belantamab mafodotin, and neutropenia (34 [33%] of 102) and anaemia (18[18%]) for pomalidomide-dexamethasone. Serious adverse events occurred in 94 (43%) of 217 and 40 (39%) of 102 patients, respectively. There were no treatment-related deaths in the belantamab mafodotin group and one (1%) in the pomalidomide-dexamethasone group due to sepsis. INTERPRETATION: Belantamab mafodotin was not associated with statistically improved progression-free survival compared with standard-of-care, but there were no new safety signals associated with its use. Belantamab mafodotin is being tested in combination regimens for relapsed or refractory multiple myeloma. FUNDING: GSK (study number 207495).
引用
- Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023. PMID: 37793771. doi:10.1016/S2352-3026(23)00243-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。